跳至主要内容
临床试验/EUCTR2010-018350-13-BE
EUCTR2010-018350-13-BE进行中(未招募)不适用

Immunogenicity, Reactogenicity and Safety of the Trivalent Influenza Subunit Vaccine Influvac® for the Season 2010/2011. An Open-Label, Baseline-Controlled Multi-Center Study in Two Groups: Adult Subjects =18 and =60 Years and Elderly Subjects = 61 Years of Age. - Influvac Annual Update 2010/2011

Abbott Biologicals B.V.0 个研究点目标入组 120 人开始时间: 2010年6月4日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
120

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. Willing and able to give informed consent and able to adhere to all protocol required study procedures.
  • 2. Men and women aged = 18 and = 60 years or = 61 years of age at the day of study vaccination.
  • 3. Being in good health as judged by medical history, physical examination (if needed) and clinical judgment of the Investigator (subjects may have underlying illnesses such as hypertension, diabetes, ischemic heart disease or hypothyroidism, as long as their symptoms/signs are controlled. If on medication for a condition, the medication dose must have been stable for at least three months preceding study vaccination).
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1. Known to be allergic to eggs, chicken protein, gentamicin or any other constituent of the vaccine.
  • 2. A serious adverse reaction after a previous (influenza) vaccination.
  • 3. Presence of any significant condition that may prohibit inclusion as determined by the investigator.
  • 4. Seasonal or pandemic influenza vaccination or laboratory confirmed seasonal or pandemic influenza infection within the previous six months before study vaccination or planned vaccination during the study period.
  • 5. A history of Guillain-Barré syndrome or active neurological disease.
  • 6. Having fever and/or presenting with an acute disease or infection on the day of study vaccination.
  • 7. Having any condition affecting the immune system e.g., autoimmune disease.
  • 8. Receipt of vaccines (live or inactivated) within four weeks before study vaccination or planned vaccination (other than with the study vaccine) during the study period.
  • 9. Using or having used medication that influences the immune system (such as corticosteroids) during the four weeks prior to the study or planned use thereof during the study. Topical use of corticosteroids (e.g., cream, ocular drops, inhalation and intranasal sprays), within the dosage noted on the product label, is allowed.
  • 10. Use of cytotoxic drugs, anticancer chemotherapy or radiation therapy within 36 months before the day of study vaccination.
  • 11. Receipt of another investigational agent within 30 days prior to study vaccination, or planned use during the study period.
  • 12. Known drug or alcohol abuse
  • 13. Planned surgery during the study period.
  • 14. Being pregnant (positive urine pregnancy test at the day of study vaccination), breastfeeding or a desire to become pregnant during the study.
  • 15. Not using a medically accepted method of birth control including abstinence during the study period.

研究者

相似试验